Regulation of the Master Regulator FOXM1 in Cancer

Overview

Journal Cell Commun Signal

Publisher Biomed Central

Specialties Biochemistry
Cell Biology

Date 2018 Sep 14

PMID 30208972

Citations 195

Authors

Guo-Bin Liao

Xin-Zhe Li

Shuo Zeng

Cheng Liu

Shi-ming Yang

Li Yang

Chang-Jiang Hu

Jian-Ying Bai

Affiliations

Soon will be listed here.

Abstract

FOXM1 (forkhead box protein M1) is a critical proliferation-associated transcription factor that is widely spatiotemporally expressed during the cell cycle. It is closely involved with the processes of cell proliferation, self-renewal, and tumorigenesis. In most human cancers, FOXM1 is overexpressed, and this indicates a poor prognosis for cancer patients. FOXM1 maintains cancer hallmarks by regulating the expression of target genes at the transcriptional level. Due to its potential role as molecular target in cancer therapy, FOXM1 was named the Molecule of the Year in 2010. However, the mechanism of FOXM1 dysregulation remains indistinct. A comprehensive understanding of FOXM1 regulation will provide novel insight for cancer and other diseases in which FOXM1 plays a major role. Here, we summarize the transcriptional regulation, post-transcriptional regulation and post-translational modifications of FOXM1, which will provide extremely important implications for novel strategies targeting FOXM1.

Citing Articles

Thiostrepton suppresses intrahepatic cholangiocarcinoma progression via FOXM1-mediated tumor-associated macrophages reprogramming.

Li Y, Jiang Y, Tong R, Ding B, Ge J, Du K Transl Oncol. 2025; 54:102327.

PMID: 39986191 PMC: 11904789. DOI: 10.1016/j.tranon.2025.102327.

Cellular and Molecular Mechanisms Modulated by Genistein in Cancer.

Naponelli V, Piscazzi A, Mangieri D Int J Mol Sci. 2025; 26(3).

PMID: 39940882 PMC: 11818640. DOI: 10.3390/ijms26031114.

FOXM1-Driven CKS1B Upregulation Promotes Pancreatic Cancer Progression and Therapeutic Resistance.

Zhang L, Wei F, Sun Q, Huang X, Zou Q, Jiang M Int J Biol Sci. 2025; 21(3):1047-1064.

PMID: 39897042 PMC: 11781179. DOI: 10.7150/ijbs.105289.

Endothelial FOXM1 and Dab2 promote diabetic wound healing.

Bhattacharjee S, Gao J, Lu Y, Eisa-Beygi S, Wu H, Li K JCI Insight. 2025; 10(2).

PMID: 39846251 PMC: 11790024. DOI: 10.1172/jci.insight.186504.

Interaction of STIL with FOXM1 regulates SF3A3 transcription in the hepatocellular carcinoma development.

Zhang H, Zhang L, Wu Z Cell Div. 2025; 20(1):1.

PMID: 39825314 PMC: 11740530. DOI: 10.1186/s13008-025-00142-4.

References

Wan L, Deng J, Xiang X, Zhang L, Yu F, Chen J . miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun. 2014; 457(2):125-32. DOI: 10.1016/j.bbrc.2014.11.039. View

Kalinichenko V, Major M, Wang X, Petrovic V, Kuechle J, Yoder H . Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 2004; 18(7):830-50. PMC: 387422. DOI: 10.1101/gad.1200704. View

Zhang H, Zhong H, Li L, Ji W, Zhang X . Overexpressed transcription factor FOXM1 contributes to the progression of colorectal cancer. Mol Med Rep. 2016; 13(3):2696-700. DOI: 10.3892/mmr.2016.4875. View

Tassi R, Todeschini P, Siegel E, Calza S, Cappella P, Ardighieri L . FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. J Exp Clin Cancer Res. 2017; 36(1):63. PMC: 5422964. DOI: 10.1186/s13046-017-0536-y. View

Petrovic V, Costa R, Lau L, Raychaudhuri P, Tyner A . Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin. Cancer Biol Ther. 2010; 9(12):1008-16. PMC: 3005150. DOI: 10.4161/cbt.9.12.11710. View

Kong F, Qu Z, Yuan H, Wang J, Zhao M, Guo Y . Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer. Oncol Rep. 2014; 31(6):2660-8. DOI: 10.3892/or.2014.3129. View

Gage M, Becares N, Louie R, Waddington K, Zhang Y, Tittanegro T . Disrupting LXRα phosphorylation promotes FoxM1 expression and modulates atherosclerosis by inducing macrophage proliferation. Proc Natl Acad Sci U S A. 2018; 115(28):E6556-E6565. PMC: 6048484. DOI: 10.1073/pnas.1721245115. View

Duan N, Hu X, Yang X, Cheng H, Zhang W . MicroRNA-370 directly targets FOXM1 to inhibit cell growth and metastasis in osteosarcoma cells. Int J Clin Exp Pathol. 2015; 8(9):10250-60. PMC: 4637548. View

Schimmel J, Eifler K, Sigurdsson J, Cuijpers S, Hendriks I, Verlaan-de Vries M . Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein. Mol Cell. 2014; 53(6):1053-66. DOI: 10.1016/j.molcel.2014.02.001. View

10.

Wang S, Ma F, Tang Z, Wu X, Cai Q, Zhang M . Long non-coding RNA H19 regulates FOXM1 expression by competitively binding endogenous miR-342-3p in gallbladder cancer. J Exp Clin Cancer Res. 2016; 35(1):160. PMC: 5048611. DOI: 10.1186/s13046-016-0436-6. View

11.

Ito T, Kohashi K, Yamada Y, Iwasaki T, Maekawa A, Kuda M . Prognostic Significance of Forkhead Box M1 (FOXM1) Expression and Antitumor Effect of FOXM1 Inhibition in Angiosarcoma. J Cancer. 2016; 7(7):823-30. PMC: 4860799. DOI: 10.7150/jca.14461. View

12.

Cheng X, Black M, Ustiyan V, Le T, Fulford L, Sridharan A . SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene. PLoS Genet. 2014; 10(9):e1004656. PMC: 4177813. DOI: 10.1371/journal.pgen.1004656. View

13.

Myatt S, Kongsema M, Man C, Kelly D, Gomes A, Khongkow P . SUMOylation inhibits FOXM1 activity and delays mitotic transition. Oncogene. 2013; 33(34):4316-29. PMC: 4096495. DOI: 10.1038/onc.2013.546. View

14.

Kongsema M, Zona S, Karunarathna U, Cabrera E, Man E, Yao S . RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment. Oncogenesis. 2016; 5(8):e252. PMC: 5007831. DOI: 10.1038/oncsis.2016.57. View

15.

Dong G, Jeong J, Lee Y, Lee S, Zhao H, Jeon R . Diarylheptanoids suppress proliferation of pancreatic cancer PANC-1 cells through modulating shh-Gli-FoxM1 pathway. Arch Pharm Res. 2017; 40(4):509-517. DOI: 10.1007/s12272-017-0905-2. View

16.

Delpuech O, Griffiths B, East P, Essafi A, Lam E, Burgering B . Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Mol Cell Biol. 2007; 27(13):4917-30. PMC: 1951505. DOI: 10.1128/MCB.01789-06. View

17.

Nandi D, Cheema P, Jaiswal N, Nag A . FoxM1: Repurposing an oncogene as a biomarker. Semin Cancer Biol. 2017; 52(Pt 1):74-84. DOI: 10.1016/j.semcancer.2017.08.009. View

18.

Chen P, Wu T, Shieh S, Wu Y, Li M, Sheu G . MnSOD promotes tumor invasion via upregulation of FoxM1-MMP2 axis and related with poor survival and relapse in lung adenocarcinomas. Mol Cancer Res. 2012; 11(3):261-71. DOI: 10.1158/1541-7786.MCR-12-0527. View

19.

Abdeljaoued S, Bettaieb I, Nasri M, Adouni O, Goucha A, Amine O . Overexpression of FOXM1 Is a Potential Prognostic Marker in Male Breast Cancer. Oncol Res Treat. 2017; 40(4):167-172. DOI: 10.1159/000458156. View

20.

Gartel A . FoxM1 inhibitors as potential anticancer drugs. Expert Opin Ther Targets. 2008; 12(6):663-5. DOI: 10.1517/14728222.12.6.663. View